On a reported basis in the quarter, earnings per share was $7.84, as compared to $7.11 in the prior year.
Adjusted earnings per share for the quarter was $7.78, a 14% increase over the prior-year amount of $6.85.
For the full-year 2019, we exceeded $3 billion in sales and achieved 5% growth in local currency.
On a U.S. dollar basis, total sales increased 3% as currencies reduced sales growth by approximately 1% in the quarter.
By region for the year, sales increased 6% in the Americas, 3% in Europe and 6% in Asia/Rest of World.
SG&A amounted to $206.7 million, a 3% increase in local currency over the prior year.
Excluding the impact of the retail decline and adjusting our guidance for the estimated coronavirus impact, we would have expected sales growth in Q1 to be in the range of 3% to 4%.
Overall, we expect good growth in our Laboratory business in 2020, although we faced more challenging comparisons after several years of very strong growth.
We again faced meaningful headwinds in the quarter due to adverse currency and impact of tariffs.
We expect the coronavirus to significantly impact sales in China in the first quarter due to the loss of selling days.
Based on market conditions today, we expect local currency sales growth to be approximately 0% to 1%.
We would expect that adjusted earnings per share in the first quarter to be in the range of $4.20 to $4.30, a growth rate of 2% to 5%.
We remain cautious on the macroeconomic environment as certain indicators are weak.
Sales were $844 million in the quarter, an increase of 4% in local currency.
